Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease.

This study has been completed.
Sponsor:
Information provided by:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov Identifier:
NCT00309725
First received: March 31, 2006
Last updated: May 17, 2011
Last verified: January 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 1999
  Estimated Primary Completion Date: No date given